StemRemedium is a private company formed in 2016 to develop innovative treatments for chronic disease and injury through breakthrough cellular technologies and medical devices. StemRemedium funds clinical research projects and establishes strategic partnerships with world-leading scientists and principal investigators in stem cell transplant therapies and regenerative medicine. StemRemedium CSC 14 cells were developed by a UC-Irvine team lead by Dr. Hans Keirstead, who has been featured on 60 Minutes and is considered one of the world’s leading pioneers in stem cell research. Dr. Keirstead’s early research confirmed the theoretical ability to produce stems cells with targeted applications. More importantly, his work has advanced beyond the research lab and is now in FDA clinical trials. Having left the university research setting, Dr. Keirstead was recently Chief Science Officer of Caladrius, Inc. (formerly NeoStem) where his stem cell work is the basis for a cure for melanoma. CIRM recently awarded Caladrius a $17.7 million grant, to help support Phase 3 clinical trials; he now serves as CEO of AiVita Biomedical, Inc. The patients involved in these trials face imminent death; they have stage 4 cancer. The Phase 3 trials are for efficacy: the medicine given might cure the patients.